These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

651 related articles for article (PubMed ID: 32820248)

  • 1. Animal and translational models of SARS-CoV-2 infection and COVID-19.
    Johansen MD; Irving A; Montagutelli X; Tate MD; Rudloff I; Nold MF; Hansbro NG; Kim RY; Donovan C; Liu G; Faiz A; Short KR; Lyons JG; McCaughan GW; Gorrell MD; Cole A; Moreno C; Couteur D; Hesselson D; Triccas J; Neely GG; Gamble JR; Simpson SJ; Saunders BM; Oliver BG; Britton WJ; Wark PA; Nold-Petry CA; Hansbro PM
    Mucosal Immunol; 2020 Nov; 13(6):877-891. PubMed ID: 32820248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scientific research progress of COVID-19/SARS-CoV-2 in the first five months.
    Li H; Liu Z; Ge J
    J Cell Mol Med; 2020 Jun; 24(12):6558-6570. PubMed ID: 32320516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development.
    Samrat SK; Tharappel AM; Li Z; Li H
    Virus Res; 2020 Oct; 288():198141. PubMed ID: 32846196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 Vaccine: A comprehensive status report.
    Kaur SP; Gupta V
    Virus Res; 2020 Oct; 288():198114. PubMed ID: 32800805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of SARS-CoV-2 vaccine candidates.
    Dong Y; Dai T; Wei Y; Zhang L; Zheng M; Zhou F
    Signal Transduct Target Ther; 2020 Oct; 5(1):237. PubMed ID: 33051445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin.
    Theoharides TC
    Biofactors; 2020 May; 46(3):306-308. PubMed ID: 32339387
    [No Abstract]   [Full Text] [Related]  

  • 7. A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition.
    Dieterle ME; Haslwanter D; Bortz RH; Wirchnianski AS; Lasso G; Vergnolle O; Abbasi SA; Fels JM; Laudermilch E; Florez C; Mengotto A; Kimmel D; Malonis RJ; Georgiev G; Quiroz J; Barnhill J; Pirofski LA; Daily JP; Dye JM; Lai JR; Herbert AS; Chandran K; Jangra RK
    Cell Host Microbe; 2020 Sep; 28(3):486-496.e6. PubMed ID: 32738193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures.
    Dinnon KH; Leist SR; Schäfer A; Edwards CE; Martinez DR; Montgomery SA; West A; Yount BL; Hou YJ; Adams LE; Gully KL; Brown AJ; Huang E; Bryant MD; Choong IC; Glenn JS; Gralinski LE; Sheahan TP; Baric RS
    Nature; 2020 Oct; 586(7830):560-566. PubMed ID: 32854108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in Studies on Structural and Remedial Aspects of Newly Born Coronavirus, SARS-CoV-2.
    Gupta SP
    Curr Top Med Chem; 2020; 20(26):2362-2378. PubMed ID: 32962613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
    Datta PK; Liu F; Fischer T; Rappaport J; Qin X
    Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of lethal human coronaviruses.
    Chen B; Tian EK; He B; Tian L; Han R; Wang S; Xiang Q; Zhang S; El Arnaout T; Cheng W
    Signal Transduct Target Ther; 2020 Jun; 5(1):89. PubMed ID: 32533062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles' heel conserved region to minimize probability of escape mutations and drug resistance.
    Robson B
    Comput Biol Med; 2020 Jun; 121():103749. PubMed ID: 32568687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.
    Catanzaro M; Fagiani F; Racchi M; Corsini E; Govoni S; Lanni C
    Signal Transduct Target Ther; 2020 May; 5(1):84. PubMed ID: 32467561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice.
    Laczkó D; Hogan MJ; Toulmin SA; Hicks P; Lederer K; Gaudette BT; Castaño D; Amanat F; Muramatsu H; Oguin TH; Ojha A; Zhang L; Mu Z; Parks R; Manzoni TB; Roper B; Strohmeier S; Tombácz I; Arwood L; Nachbagauer R; Karikó K; Greenhouse J; Pessaint L; Porto M; Putman-Taylor T; Strasbaugh A; Campbell TA; Lin PJC; Tam YK; Sempowski GD; Farzan M; Choe H; Saunders KO; Haynes BF; Andersen H; Eisenlohr LC; Weissman D; Krammer F; Bates P; Allman D; Locci M; Pardi N
    Immunity; 2020 Oct; 53(4):724-732.e7. PubMed ID: 32783919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies.
    Papageorgiou AC; Mohsin I
    Cells; 2020 Oct; 9(11):. PubMed ID: 33105869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
    Giovane RA; Rezai S; Cleland E; Henderson CE
    Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular structure analyses suggest strategies to therapeutically target SARS-CoV-2.
    Zhang Y; Kutateladze TG
    Nat Commun; 2020 Jun; 11(1):2920. PubMed ID: 32523109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Could a specific ACE2 activator drug improve the clinical outcome of SARS-CoV-2? A potential pharmacological insight.
    Nicolau LAD; Nolêto IRSG; Medeiros JVR
    Expert Rev Clin Pharmacol; 2020 Aug; 13(8):807-811. PubMed ID: 32686527
    [No Abstract]   [Full Text] [Related]  

  • 19. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
    Hosoki K; Chakraborty A; Sur S
    J Allergy Clin Immunol; 2020 Aug; 146(2):285-299. PubMed ID: 32624257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present α-gal epitopes.
    Galili U
    Vaccine; 2020 Sep; 38(42):6487-6499. PubMed ID: 32907757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.